A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target

Chethan Gejjalagere Honnappa, Unnikrishnan Mazhuvancherry Kesavan

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Inflammatory diseases are complex, multi-factorial outcomes of evolutionarily conserved tissue repair processes. For decades, non-steroidal anti-inflammatory drugs and cyclooxygenase inhibitors, the primary drugs of choice for the management of inflammatory diseases, addressed individual targets in the arachidonic acid pathway. Unsatisfactory safety and efficacy profiles of the above have necessitated the development of multi-target agents to treat complex inflammatory diseases. Current anti-inflammatory therapies still fall short of clinical needs and the clinical trial results of multi-target therapeutics are anticipated. Additionally, new drug targets are emerging with improved understanding of molecular mechanisms controlling the pathophysiology of inflammation. This review presents an outline of small molecules and drug targets in anti-inflammatory therapeutics with a summary of a newly identified target AMP-activated protein kinase, which constitutes a novel therapeutic pathway in inflammatory pathology.

Original languageEnglish
Pages (from-to)562-571
Number of pages10
JournalInternational Journal of Immunopathology and Pharmacology
Volume29
Issue number4
Publication statusPublished - 01-12-2016
Externally publishedYes

Fingerprint

AMP-Activated Protein Kinases
Anti-Inflammatory Agents
Pharmaceutical Preparations
Cyclooxygenase Inhibitors
Therapeutics
Disease Management
Arachidonic Acid
Clinical Trials
Pathology
Inflammation
Safety

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

@article{b028d66b37af41e697df4f193df9e684,
title = "A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target",
abstract = "Inflammatory diseases are complex, multi-factorial outcomes of evolutionarily conserved tissue repair processes. For decades, non-steroidal anti-inflammatory drugs and cyclooxygenase inhibitors, the primary drugs of choice for the management of inflammatory diseases, addressed individual targets in the arachidonic acid pathway. Unsatisfactory safety and efficacy profiles of the above have necessitated the development of multi-target agents to treat complex inflammatory diseases. Current anti-inflammatory therapies still fall short of clinical needs and the clinical trial results of multi-target therapeutics are anticipated. Additionally, new drug targets are emerging with improved understanding of molecular mechanisms controlling the pathophysiology of inflammation. This review presents an outline of small molecules and drug targets in anti-inflammatory therapeutics with a summary of a newly identified target AMP-activated protein kinase, which constitutes a novel therapeutic pathway in inflammatory pathology.",
author = "{Gejjalagere Honnappa}, Chethan and {Mazhuvancherry Kesavan}, Unnikrishnan",
year = "2016",
month = "12",
day = "1",
language = "English",
volume = "29",
pages = "562--571",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "4",

}

A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK : An emerging target. / Gejjalagere Honnappa, Chethan; Mazhuvancherry Kesavan, Unnikrishnan.

In: International Journal of Immunopathology and Pharmacology, Vol. 29, No. 4, 01.12.2016, p. 562-571.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK

T2 - An emerging target

AU - Gejjalagere Honnappa, Chethan

AU - Mazhuvancherry Kesavan, Unnikrishnan

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Inflammatory diseases are complex, multi-factorial outcomes of evolutionarily conserved tissue repair processes. For decades, non-steroidal anti-inflammatory drugs and cyclooxygenase inhibitors, the primary drugs of choice for the management of inflammatory diseases, addressed individual targets in the arachidonic acid pathway. Unsatisfactory safety and efficacy profiles of the above have necessitated the development of multi-target agents to treat complex inflammatory diseases. Current anti-inflammatory therapies still fall short of clinical needs and the clinical trial results of multi-target therapeutics are anticipated. Additionally, new drug targets are emerging with improved understanding of molecular mechanisms controlling the pathophysiology of inflammation. This review presents an outline of small molecules and drug targets in anti-inflammatory therapeutics with a summary of a newly identified target AMP-activated protein kinase, which constitutes a novel therapeutic pathway in inflammatory pathology.

AB - Inflammatory diseases are complex, multi-factorial outcomes of evolutionarily conserved tissue repair processes. For decades, non-steroidal anti-inflammatory drugs and cyclooxygenase inhibitors, the primary drugs of choice for the management of inflammatory diseases, addressed individual targets in the arachidonic acid pathway. Unsatisfactory safety and efficacy profiles of the above have necessitated the development of multi-target agents to treat complex inflammatory diseases. Current anti-inflammatory therapies still fall short of clinical needs and the clinical trial results of multi-target therapeutics are anticipated. Additionally, new drug targets are emerging with improved understanding of molecular mechanisms controlling the pathophysiology of inflammation. This review presents an outline of small molecules and drug targets in anti-inflammatory therapeutics with a summary of a newly identified target AMP-activated protein kinase, which constitutes a novel therapeutic pathway in inflammatory pathology.

UR - http://www.scopus.com/inward/record.url?scp=85016923625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016923625&partnerID=8YFLogxK

M3 - Review article

C2 - 27707958

AN - SCOPUS:85016923625

VL - 29

SP - 562

EP - 571

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 4

ER -